Home / Latest Reports / Monoclonal Antibodies Market

Monoclonal Antibodies Market by Source Type, Indication and End User - Global Industry Analysis & Forecast to 2027

Published On : June 2022 Pages : 152 Category: Pharma & Healthcare Report Code : HC063868

SEGMENTS & REGIONS:

  • Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa

Monoclonal Antibodies Market by Source Type (Chimeric, Human, Murine, Humanized) Indication (Autoimmune Diseases, Infectious Diseases, Cancer, Inflammatory Diseases, Microbial Diseases, Others) End User (Research Institutes, Hospitals, Others) - Global Industry Analysis & Forecast to 2027

Industry Outlook and Trend Analysis

The Monoclonal Antibodies Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Monoclonal antibodies are copies of a one of a kind parental cell obtained from indistinguishable insusceptible cells. These antibodies can tie to a specific antigen when managed, as they have monovalent liking. Monoclonal antibodies fill in as a significant apparatus to distinguish or purge substances, inferable from their site particularity; consequently, they have significant end use in molecular biology, biochemistry, and medication.

Drivers and Restraints

Development in demand for customized meds and flood being developed of helpful antibodies drives the monoclonal antibodies market. Also, focal points, for example, specificity, homogeneity, and enormous scale generation; and less reactions identified with substitute medications are anticipated to support the market development.

Regional Insights

North America held the most extreme share in 2017 because of the existence of settled healthcare infrastructure.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Competitive Analysis                         

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

  • GlaxoSmithKline plc
  • Merck & Co., Inc
  • Eli Lilly and Company
  • Daiichi Sankyo Company, Ltd
  • Bristol Myers Squibb Co
  • Biogen Inc
  • Sanofi Genzyme
  • Novo Nordisk A/S
  • Pfizer, Inc
  • Novartis AG

Some of the key questions answered by the report are:

  • What was the market size in 2017 and forecast from 2017 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         Monoclonal Antibodies Market, By Source Type, Estimates and Forecast, 2017-2027 ($Million)

o    Chimeric

o    Human

o    Murine

o    Humanized

·         Monoclonal Antibodies Market, By Indication, Estimates and Forecast, 2017-2027 ($Million)

o    Autoimmune Diseases

o    Infectious Diseases

o    Cancer

o    Inflammatory Diseases

o    Microbial Diseases

o    Others

·         Monoclonal Antibodies Market, By End User, Estimates and Forecast, 2017-2027 ($Million)

o    Research Institutes

o    Hospitals

o    Others

·         Monoclonal Antibodies Market, By Key Players

o    GlaxoSmithKline plc

o    Merck & Co., Inc

o    Eli Lilly and Company

o    Daiichi Sankyo Company, Ltd

o    Bristol Myers Squibb Co

o    Biogen Inc

o    Sanofi Genzyme

o    Novo Nordisk A/S

o    Pfizer, Inc

o    Novartis AG

·         Monoclonal Antibodies Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

o    North America

§  North America Monoclonal Antibodies Market, By Country

o    U.S. Monoclonal Antibodies Market

o    Canada Monoclonal Antibodies Market

o    Mexico Monoclonal Antibodies Market

o    Europe

§  Europe Monoclonal Antibodies Market, By Country

o    Germany Monoclonal Antibodies Market

o    UK Monoclonal Antibodies Market

o    France Monoclonal Antibodies Market

o    Russia Monoclonal Antibodies Market

o    Italy Monoclonal Antibodies Market

o    Rest of Europe Monoclonal Antibodies Market

o    Asia-Pacific

§  Asia-Pacific Monoclonal Antibodies Market, By Country

o    China Monoclonal Antibodies Market

o    Japan Monoclonal Antibodies Market

o    South Korea Monoclonal Antibodies Market

o    India Monoclonal Antibodies Market

o    Southeast Asia Monoclonal Antibodies Market

o    Rest of Asia-Pacific Monoclonal Antibodies Market

o    South America

§  South America Monoclonal Antibodies Market

o    Brazil Monoclonal Antibodies Market

o    Argentina Monoclonal Antibodies Market

o    Columbia Monoclonal Antibodies Market

o    Rest of South America Monoclonal Antibodies Market

o    Middle East and Africa

§  Middle East and Africa Monoclonal Antibodies Market

o    Saudi Arabia Monoclonal Antibodies Market

o    UAE Monoclonal Antibodies Market

o    Egypt Monoclonal Antibodies Market

o    Nigeria Monoclonal Antibodies Market

o    South Africa Monoclonal Antibodies Market

o    Rest of MEA Monoclonal Antibodies Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       Monoclonal Antibodies Market, By Source Type

5.1.     Introduction

5.2.     Global Monoclonal Antibodies Revenue and Market Share by Source Type (2017-2027)

5.2.1.  Global Monoclonal Antibodies Revenue and Revenue Share by Source Type (2017-2027)

5.3.     Chimeric

5.3.1.  Global Chimeric Revenue and Growth Rate (2017-2027)

5.4.     Human

5.4.1.  Global Human Revenue and Growth Rate (2017-2027)

5.5.     Murine

5.5.1.  Global Murine Revenue and Growth Rate (2017-2027)

5.6.     Humanized

5.6.1.  Global Humanized Revenue and Growth Rate (2017-2027)

6.       Monoclonal Antibodies Market, By Indication

6.1.     Introduction

6.2.     Global Monoclonal Antibodies Revenue and Market Share by Indication  (2017-2027)

6.2.1.  Global Monoclonal Antibodies Revenue and Revenue Share by Indication  (2017-2027)

6.3.     Autoimmune Diseases

6.3.1.  Global Autoimmune Diseases Revenue and Growth Rate (2017-2027)

6.4.     Infectious Diseases

6.4.1.  Global Infectious Diseases Revenue and Growth Rate (2017-2027)

6.5.     Cancer

6.5.1.  Global Cancer Revenue and Growth Rate (2017-2027)

6.6.     Inflammatory Diseases

6.6.1.  Global Inflammatory Diseases Revenue and Growth Rate (2017-2027)

6.7.     Microbial Diseases

6.7.1.  Global Microbial Diseases Revenue and Growth Rate (2017-2027)

6.8.     Others

6.8.1.  Global Others Revenue and Growth Rate (2017-2027)

7.       Monoclonal Antibodies Market, By End User

7.1.     Introduction

7.2.     Global Monoclonal Antibodies Revenue and Market Share by End User (2017-2027)

7.2.1.  Global Monoclonal Antibodies Revenue and Revenue Share by End User (2017-2027)

7.3.     Research Institutes

7.3.1.  Global Research Institutes Revenue and Growth Rate (2017-2027)

7.4.     Hospitals

7.4.1.  Global Hospitals Revenue and Growth Rate (2017-2027)

7.5.     Others

7.5.1.  Global Others Revenue and Growth Rate (2017-2027)

8.       Monoclonal Antibodies Market, By Region

8.1.     Introduction

8.2.     Global Monoclonal Antibodies Revenue and Market Share by Regions

8.2.1.  Global Monoclonal Antibodies Revenue by Regions (2017-2027)

8.3.     North America Monoclonal Antibodies by Countries

8.3.1.  North America Monoclonal Antibodies Revenue and Growth Rate (2017-2027)

8.3.2.  North America Monoclonal Antibodies Revenue (Million USD) by Countries (2017-2027)

8.3.3.  United States

8.3.3.1.  United States Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.3.4.  Canada

8.3.4.1.  Canada Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.3.5.  Mexico

8.3.5.1.  Mexico Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.4.     Europe Monoclonal Antibodies by Countries

8.4.1.  Europe Monoclonal Antibodies Revenue and Growth Rate (2017-2027)

8.4.2.  Europe Monoclonal Antibodies Revenue (Million USD) by Countries (2017-2027)

8.4.3.  Germany

8.4.3.1.  Germany Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.4.4.  France

8.4.4.1.  France Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.4.5.  UK

8.4.5.1.  UK Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.4.6.  Russia

8.4.6.1.  Russia Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.4.7.  Italy

8.4.7.1.  Italy Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.4.8.  Rest of Europe

8.4.8.1.  Rest of Europe Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.5.     Asia-Pacific Monoclonal Antibodies by Countries

8.5.1.  Asia-Pacific Monoclonal Antibodies Revenue and Growth Rate (2017-2027)

8.5.2.  Asia-Pacific Monoclonal Antibodies Revenue (Million USD) by Countries (2017-2027)

8.5.3.  China

8.5.3.1.  China Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.5.4.  Japan

8.5.4.1.  Japan Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.5.5.  Korea

8.5.5.1.  Korea Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.5.6.  India

8.5.6.1.  India Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.5.7.  Southeast Asia

8.5.7.1.  Southeast Asia Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.5.8.  Rest of Asia-Pacific

8.5.8.1.  Rest of Asia-Pacific Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.6.     South America Monoclonal Antibodies by Countries

8.6.1.  South America Monoclonal Antibodies Revenue and Growth Rate (2017-2027)

8.6.2.  South America Monoclonal Antibodies Revenue (Million USD) by Countries (2017-2027)

8.6.3.  Brazil

8.6.3.1.  Brazil Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.6.4.  Argentina

8.6.4.1.  Argentina Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.6.5.  Columbia

8.6.5.1.  Columbia Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.6.6.  Rest of South America

8.6.6.1.  Rest of South America Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.     Middle East and Africa Monoclonal Antibodies by Countries

8.7.1.  Middle East and Africa Monoclonal Antibodies Revenue and Growth Rate (2017-2027)

8.7.2.  Middle East and Africa Monoclonal Antibodies Revenue (Million USD) by Countries (2017-2027)

8.7.3.  Saudi Arabia

8.7.3.1.  Saudi Arabia Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.4.  United Arab Emirates

8.7.4.1.  United Arab Emirates Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.5.  Egypt

8.7.5.1.  Egypt Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.6.  Nigeria

8.7.6.1.  Nigeria Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.7.  South Africa

8.7.7.1.  South Africa Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.8.  Turkey

8.7.8.1.  Turkey Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.9.  Rest of Middle East and Africa

8.7.9.1.  Rest of Middle East and Africa Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

9.       Company Profiles

9.1.     GlaxoSmithKline plc

9.1.1.  Business Overview

9.1.2.   Service Portfolio

9.1.3.  Strategic Developments

9.1.4.  Financial Overview

9.2.     Merck & Co., Inc

9.2.1.  Business Overview

9.2.2.   Service Portfolio

9.2.3.  Strategic Developments

9.2.4.  Financial Overview

9.3.     Eli Lilly and Company

9.3.1.  Business Overview

9.3.2.   Service Portfolio

9.3.3.  Strategic Developments

9.3.4.  Financial Overview

9.4.     Daiichi Sankyo Company, Ltd

9.4.1.  Business Overview

9.4.2.   Service Portfolio

9.4.3.  Strategic Developments

9.4.4.  Financial Overview

9.5.     Bristol Myers Squibb Co

9.5.1.  Business Overview

9.5.2.   Service Portfolio

9.5.3.  Strategic Developments

9.5.4.  Financial Overview

9.6.     Biogen Inc

9.6.1.  Business Overview

9.6.2.   Service Portfolio

9.6.3.  Strategic Developments

9.6.4.  Financial Overview

9.7.     Sanofi Genzyme

9.7.1.  Business Overview

9.7.2.   Service Portfolio

9.7.3.  Strategic Developments

9.7.4.  Financial Overview

9.8.     Novo Nordisk A/S

9.8.1.  Business Overview

9.8.2.   Service Portfolio

9.8.3.  Strategic Developments

9.8.4.  Financial Overview

9.9.     Pfizer, Inc

9.9.1.  Business Overview

9.9.2.   Service Portfolio

9.9.3.  Strategic Developments

9.9.4.  Financial Overview

9.10. Novartis AG

9.10.1.      Business Overview

9.10.2.       Service Portfolio

9.10.3.      Strategic Developments

9.10.4.      Financial Overview

10.    Monoclonal Antibodies Market Forecast (2017-2027)

10.1. Global Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2027)

10.2. Monoclonal Antibodies Market Forecast by Regions (2017-2027)

10.2.1.      North America Monoclonal Antibodies Market Forecast (2017-2027)

10.2.1.1. United States Monoclonal Antibodies Market Forecast (2017-2027)

10.2.1.2. Canada Monoclonal Antibodies Market Forecast (2017-2027)

10.2.1.3. Mexico Monoclonal Antibodies Market Forecast (2017-2027)

10.2.2.      Europe Monoclonal Antibodies Market Forecast (2017-2027)

10.2.2.1. Germany Monoclonal Antibodies Market Forecast (2017-2027)

10.2.2.2. France Monoclonal Antibodies Market Forecast (2017-2027)

10.2.2.3. UK Monoclonal Antibodies Market Forecast (2017-2027)

10.2.2.4. Russia Monoclonal Antibodies Market Forecast (2017-2027)

10.2.2.5. Italy Monoclonal Antibodies Market Forecast (2017-2027)

10.2.2.6. Rest of Europe Monoclonal Antibodies Market Forecast (2017-2027)

10.2.3.      Asia-Pacific Monoclonal Antibodies Market Forecast (2017-2027)

10.2.3.1. China Monoclonal Antibodies Market Forecast (2017-2027)

10.2.3.2. Japan Monoclonal Antibodies Market Forecast (2017-2027)

10.2.3.3. Korea Monoclonal Antibodies Market Forecast (2017-2027)

10.2.3.4. India Monoclonal Antibodies Market Forecast (2017-2027)

10.2.3.5. Southeast Asia Monoclonal Antibodies Market Forecast (2017-2027)

10.2.3.6. Rest of Asia-Pacific Monoclonal Antibodies Market Forecast (2017-2027)

10.2.4.      South America Monoclonal Antibodies Market Forecast (2017-2027)

10.2.4.1. Brazil Monoclonal Antibodies Market Forecast (2017-2027)

10.2.4.2. Argentina Monoclonal Antibodies Market Forecast (2017-2027)

10.2.4.3. Columbia Monoclonal Antibodies Market Forecast (2017-2027)

10.2.4.4. Rest of South America Monoclonal Antibodies Market Forecast (2017-2027)

10.2.5.      Middle East and Africa Monoclonal Antibodies Market Forecast (2017-2027)

10.2.5.1. Saudi Arabia Monoclonal Antibodies Market Forecast (2017-2027)

10.2.5.2. United Arab Emirates Monoclonal Antibodies Market Forecast (2017-2027)

10.2.5.3. Egypt Monoclonal Antibodies Market Forecast (2017-2027)

10.2.5.4. Nigeria Monoclonal Antibodies Market Forecast (2017-2027)

10.2.5.5. South Africa Monoclonal Antibodies Market Forecast (2017-2027)

10.2.5.6. Turkey Monoclonal Antibodies Market Forecast (2017-2027)

10.2.5.7. Rest of Middle East and Africa Monoclonal Antibodies Market Forecast (2017-2027)

10.3. Monoclonal Antibodies Market Forecast by Source Type (2017-2027)

10.3.1.      Monoclonal Antibodies Forecast by Source Type (2017-2027)

10.3.2.      Monoclonal Antibodies Market Share Forecast by Source Type (2017-2027)

10.4. Monoclonal Antibodies Market Forecast by Indication  (2017-2027)

10.4.1.      Monoclonal Antibodies Forecast by Indication  (2017-2027)

10.4.2.      Monoclonal Antibodies Market Share Forecast by Indication  (2017-2027)

10.5. Monoclonal Antibodies Market Forecast by End User (2017-2027)

10.5.1.      Monoclonal Antibodies Forecast by End User (2017-2027)

10.5.2.      Monoclonal Antibodies Market Share Forecast by End User (2017-2027)

List of Tables

List of Tables and Figures:

Figure United States Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Monoclonal Antibodies Revenue and Revenue Share by Source Type (2017-2018)
Figure Global Chimeric Revenue and Growth Rate (2017-2018)
Figure Global Human Revenue and Growth Rate (2017-2018)
Figure Global Murine Revenue and Growth Rate (2017-2018)
Figure Global Humanized Revenue and Growth Rate (2017-2018)
Table Global Monoclonal Antibodies Revenue and Revenue Share by Indication (2017-2018)
Figure Global Autoimmune Diseases Revenue and Growth Rate (2017-2018)
Figure Global Infectious Diseases Revenue and Growth Rate (2017-2018)
Figure Global Cancer Revenue and Growth Rate (2017-2018)
Figure Global Inflammatory Diseases Revenue and Growth Rate (2017-2018)
Figure Global Microbial Diseases Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Monoclonal Antibodies Revenue and Revenue Share by End User (2017-2018)
Figure Global Research Institutes Revenue and Growth Rate (2017-2018)
Figure Global Hospitals Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Monoclonal Antibodies Revenue by Regions (2017-2018)
Figure North America Monoclonal Antibodies Growth Rate (2017-2018)
Figure North America Monoclonal Antibodies Revenue and Growth Rate (2017-2018)
Figure North America Monoclonal Antibodies by Countries (2017-2018)
Figure North America Monoclonal Antibodies Revenue (Million USD) by Countries (2017-2018)
Figure United States Monoclonal Antibodies Growth Rate (2017-2018)
Figure United States Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Monoclonal Antibodies Growth Rate (2017-2018)
Figure Canada Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Monoclonal Antibodies Growth Rate (2017-2018)
Figure Mexico Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Monoclonal Antibodies Growth Rate (2017-2018)
Figure Europe Monoclonal Antibodies Revenue and Growth Rate (2017-2018)
Figure Europe Monoclonal Antibodies by Countries (2017-2018)
Figure Europe Monoclonal Antibodies Revenue (Million USD) by Countries (2017-2018)
Figure Germany Monoclonal Antibodies Growth Rate (2017-2018)
Figure Germany Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Monoclonal Antibodies Growth Rate (2017-2018)
Figure France Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Monoclonal Antibodies Growth Rate (2017-2018)
Figure UK Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Monoclonal Antibodies Growth Rate (2017-2018)
Figure Russia Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Monoclonal Antibodies Growth Rate (2017-2018)
Figure Italy Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Monoclonal Antibodies Growth Rate (2017-2018)
Figure Rest of Europe Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Monoclonal Antibodies Growth Rate (2017-2018)
Figure Asia-Pacific Monoclonal Antibodies Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Monoclonal Antibodies by Countries (2017-2018)
Figure Asia-Pacific Monoclonal Antibodies Revenue (Million USD) by Countries (2017-2018)
Figure China Monoclonal Antibodies Growth Rate (2017-2018)
Figure China Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Monoclonal Antibodies Growth Rate (2017-2018)
Figure Japan Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Monoclonal Antibodies Growth Rate (2017-2018)
Figure Korea Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Monoclonal Antibodies Growth Rate (2017-2018)
Figure India Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Monoclonal Antibodies Growth Rate (2017-2018)
Figure Southeast Asia Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Monoclonal Antibodies Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Monoclonal Antibodies Growth Rate (2017-2018)
Figure South America Monoclonal Antibodies Revenue and Growth Rate (2017-2018)
Figure South America Monoclonal Antibodies by Countries (2017-2018)
Figure South America Monoclonal Antibodies Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Monoclonal Antibodies Growth Rate (2017-2018)
Figure Brazil Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Monoclonal Antibodies Growth Rate (2017-2018)
Figure Argentina Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Monoclonal Antibodies Growth Rate (2017-2018)
Figure Columbia Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Monoclonal Antibodies Growth Rate (2017-2018)
Figure Rest of South America Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Monoclonal Antibodies Growth Rate (2017-2018)
Figure Middle East and Africa Monoclonal Antibodies Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Monoclonal Antibodies by Countries (2017-2018)
Figure Middle East and Africa Monoclonal Antibodies Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Monoclonal Antibodies Growth Rate (2017-2018)
Figure Saudi Arabia Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Monoclonal Antibodies Growth Rate (2017-2018)
Figure United Arab Emirates Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Monoclonal Antibodies Growth Rate (2017-2018)
Figure Egypt Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Monoclonal Antibodies Growth Rate (2017-2018)
Figure Nigeria Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Monoclonal Antibodies Growth Rate (2017-2018)
Figure South Africa Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Monoclonal Antibodies Growth Rate (2017-2018)
Figure Turkey Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Monoclonal Antibodies Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2017-2018)
Table GlaxoSmithKline plc Monoclonal Antibodies Financial Overview
Table Merck & Co., Inc Monoclonal Antibodies Financial Overview
Table Eli Lilly and Company Monoclonal Antibodies Financial Overview
Table Daiichi Sankyo Company, Ltd Monoclonal Antibodies Financial Overview
Table Bristol Myers Squibb Co Monoclonal Antibodies Financial Overview
Table Biogen Inc Monoclonal Antibodies Financial Overview
Table Sanofi Genzyme Monoclonal Antibodies Financial Overview
Table Novo Nordisk A/S Monoclonal Antibodies Financial Overview
Table Pfizer, Inc Monoclonal Antibodies Financial Overview
Table Novartis AG Monoclonal Antibodies Financial Overview
Figure Global Monoclonal Antibodies Revenue (Millions USD) and Growth Rate (2018-2025)
Table Monoclonal Antibodies Market Forecast by Regions (2018-2025)
Figure North America Monoclonal Antibodies Market Forecast (2018-2025)
Figure United States Monoclonal Antibodies Market Forecast (2018-2025)
Figure Canada Monoclonal Antibodies Market Forecast (2018-2025)
Figure Mexico Monoclonal Antibodies Market Forecast (2018-2025)
Figure Europe Monoclonal Antibodies Market Forecast (2018-2025)
Figure Germany Monoclonal Antibodies Market Forecast (2018-2025)
Figure France Monoclonal Antibodies Market Forecast (2018-2025)
Figure UK Monoclonal Antibodies Market Forecast (2018-2025)
Figure Russia Monoclonal Antibodies Market Forecast (2018-2025)
Figure Italy Monoclonal Antibodies Market Forecast (2018-2025)
Figure Rest of Europe Monoclonal Antibodies Market Forecast (2018-2025)
Figure Asia-Pacific Monoclonal Antibodies Market Forecast (2018-2025)
Figure China Monoclonal Antibodies Market Forecast (2018-2025)
Figure Japan Monoclonal Antibodies Market Forecast (2018-2025)
Figure Korea Monoclonal Antibodies Market Forecast (2018-2025)
Figure India Monoclonal Antibodies Market Forecast (2018-2025)
Figure Southeast Asia Monoclonal Antibodies Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Monoclonal Antibodies Market Forecast (2018-2025)
Figure South America Monoclonal Antibodies Market Forecast (2018-2025)
Figure Brazil Monoclonal Antibodies Market Forecast (2018-2025)
Figure Argentina Monoclonal Antibodies Market Forecast (2018-2025)
Figure Columbia Monoclonal Antibodies Market Forecast (2018-2025)
Figure Rest of South America Monoclonal Antibodies Market Forecast (2018-2025)
Figure Middle East and Africa Monoclonal Antibodies Market Forecast (2018-2025)
Figure Saudi Arabia Monoclonal Antibodies Market Forecast (2018-2025)
Figure United Arab Emirates Monoclonal Antibodies Market Forecast (2018-2025)
Figure Egypt Monoclonal Antibodies Market Forecast (2018-2025)
Figure Nigeria Monoclonal Antibodies Market Forecast (2018-2025)
Figure South Africa Monoclonal Antibodies Market Forecast (2018-2025)
Figure Turkey Monoclonal Antibodies Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Monoclonal Antibodies Market Forecast (2018-2025)
Figure Global Monoclonal Antibodies Forecast by Source Type (2018-2025)
Figure Global Monoclonal Antibodies Market Share Forecast by Source Type (2018-2025)
Figure Global Monoclonal Antibodies Forecast by Source Type (2018-2025)
Figure Global Monoclonal Antibodies Forecast by Indication (2018-2025)
Figure Global Monoclonal Antibodies Market Share Forecast by Indication (2018-2025)
Figure Global Monoclonal Antibodies Forecast by Indication (2018-2025)
Figure Global Monoclonal Antibodies Forecast by End User (2018-2025)
Figure Global Monoclonal Antibodies Market Share Forecast by End User (2018-2025)
Figure Global Monoclonal Antibodies Forecast by End User (2018-2025)

Please Note: Data related to the Companies are subject to Availability.

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

Request Sample Enquire Before Buying Request for Customization

Request Sample